Trillium Therapeutics Inc. (TRIL)
| Market Cap | 1.89B |
| Revenue (ttm) | 43,000 |
| Net Income (ttm) | 33.87M |
| Shares Out | 103.78M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 655,310 |
| Open | 17.87 |
| Previous Close | 17.86 |
| Day's Range | 17.80 - 17.94 |
| 52-Week Range | 5.80 - 20.96 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 20.26 (+13.1%) |
| Est. Earnings Date | Nov 15, 2021 |
About TRIL
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company ...
Financial Performance
In 2020, TRIL's revenue was 148,000, an increase of 19.35% compared to the previous year's 124,000. Losses were -59.35 million, 55.8% more than in 2019.
Financial numbers in millions CADFinancial StatementsAnalyst Forecast
According to 7 analysts, the average rating for TRIL stock is "Strong Buy." The 12-month stock price forecast is 20.26, which is an increase of 13.11% from the latest price.
News
New Strong Sell Stocks for September 15th
ARCE, NSSC, PAGP, TRIL, and VALE have been added to the Zacks Rank #5 (Strong Sell) List on September 15, 2021.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRIL
NEW YORK, Sept. 11, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Actio...
Why Investors Should Love Pfizer's Acquisition of Trillium
This deal checks off several boxes for Pfizer.
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion
Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.
Trillium Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Trilliu...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Trillium Therapeutics Inc. (NASDAQ: TRIL) to Pfizer Inc. for $18.50 per share in cash...
Pfizer To Buy Cancer Biotech Company Trillium For $2.3 Million
What do you do when you're brimming with billions of dollars in new vaccine revenue? You splurge, of course!
Dual Wins for Pfizer Mean Big Jumps for These 2 Stocks
The drugmaker's own stock is up 3% Monday morning, but that's nothing compared to the impact it's having on a couple of other healthcare companies.
TRIL Stock: The Huge $2.3B Deal Sending Trillium Therapeutics Up 200%
TRIL stock is soaring to nearly triple its Friday prices. Pfizer is acquiring the oncology company in a multi-billion dollar deal.
Pfizer to buy cancer drug maker Trillium for $2.3B
Pfizer said it will pay $18.50 a share for the Cambridge, Massachusetts-based drug maker Trillium.
Why Trillium Therapeutics Stock Is Skyrocketing Today
Pfizer may have gotten a fantastic deal on this clinical-stage oncology company.
Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights
Pfizer Inc (NYSE: PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ: TRIL) for $18.50 per share, equivalent to an implied equity value of $2.26 billion. The offer price represents a 118% prem...
Trillium Therapeutics shares soar on Pfizer's $2.26B deal
Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.
Pfizer to buy Trillium Therapeutics in $2.26 billion deal
Pfizer Inc said on Monday it would buy shares of Trillium Therapeutics Inc that it does not already own in a deal that values the cancer drugs maker at $2.26 billion.
Pfizer to Acquire Trillium Therapeutics Inc.
Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results
CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidin...
CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...
$5,000 Invested in These 3 Healthcare Stocks Could Make You Rich Over the Next 10 Years
These companies could upend the industry in the years ahead.
This Biotech Stock Is Too Cheap to Ignore
Wall Street's short attention span has created an attractive entry point in this once-loved biotech.
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidin...
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...
Trillium Therapeutics Joins Russell 2000® and 3000® Indices
CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies ...
Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the tr...
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, to...